These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38049114)

  • 21. Comparison of Hemostatic Outcomes in Patients Receiving Fixed-Dose vs. Weight-Based 4-Factor Prothrombin Complex Concentrate.
    Kim C; Cottingham L; Eberwein K; Komyathy K; Ratliff PD
    J Emerg Med; 2020 Jul; 59(1):25-32. PubMed ID: 32536491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prothrombin Complex Concentrates for Warfarin Reversal Before Heart Transplantation.
    Wanek MR; Hodges K; Persaud RA; Lam SW; Soltesz EG; Tong MZ; Moazami N
    Ann Thorac Surg; 2019 May; 107(5):1409-1415. PubMed ID: 30476474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial.
    Smith MM; Schroeder DR; Nelson JA; Mauermann WJ; Welsby IJ; Pochettino A; Montonye BL; Assawakawintip C; Nuttall GA
    JAMA Surg; 2022 Sep; 157(9):757-764. PubMed ID: 35767271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
    Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
    J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study.
    Adkins BD; Shaim H; Abid A; Gonzalez A; DeAnda A; Yates SG
    J Thromb Thrombolysis; 2023 Jan; 55(1):74-82. PubMed ID: 35699871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
    Fuh L; Goldstein JN; Hayes BD
    J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing.
    Chiasakul T; Crowther M; Cuker A
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100107. PubMed ID: 37063756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
    Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
    Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Institution of prothrombin complex concentrate protocols is associated with a reduction in plasma administration at a Tertiary Care Hospital.
    Carabini LM; Budd AN; Bochey P; Shayan S; Ramsey G; McCarthy RJ
    J Clin Anesth; 2021 Jun; 70():110164. PubMed ID: 33485109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of prothrombin complex concentrate as a warfarin reversal agent in pediatric patients undergoing orthotopic heart transplantation.
    Sisti DJ; Williams GD; Ding V; Long J; Maeda K; Chen S; Navaratnam M
    Paediatr Anaesth; 2020 May; 30(5):564-570. PubMed ID: 32037665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.